…
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, infectious diseases, and other serious conditions in Massachusetts. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV and SQZ-eAPC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
SQZ Biotechnologies is a clinical-stage biotechnology company developing cell therapies using a proprietary microfluidic Cell Squeeze platform that transiently disrupts cell membranes to deliver therapeutic payloads for oncology and other indications. Long-term growth drivers include successful clinical proof-of-concept, expansion of platform applications, and partnerships or scalable manufacturing that may benefit commercialization prospects and support revenue generation.
The principal investment risks are clinical and regulatory failure, high cash burn with ongoing financing needs, and competition from established cell-therapy developers and alternative modalities.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | -71.64M | -79.46M | -68.74M | -50.52M | -32.20M |
| Net income | -71.64M | -79.46M | -68.74M | -50.52M | -32.20M |
| Selling general administrative | 21.10M | 26.32M | 25.72M | 20.51M | 18.27M |
| Reconciled depreciation | 11.45M | 11.68M | 11.03M | 10.94M | 4.36M |
| Ebit | - | -75.83M | -68.77M | -51.06M | -34.27M |
| Ebitda | - | -64.14M | -57.74M | -40.12M | -27.85M |
| Operating income | -60.77M | -75.83M | -68.77M | -51.06M | -34.27M |
| Interest expense | - | - | - | - | 0.00M |
| Interest income | 1.62M | 1.22M | 0.04M | 0.55M | 2.07M |
| Net interest income | 1.62M | 1.22M | 0.04M | 0.55M | 2.07M |
| Total revenue | 12.20M | 21.03M | 27.10M | 21.00M | 19.32M |
| Total operating expenses | 72.96M | 96.85M | 95.87M | 72.06M | 53.58M |
| Total other income expense net | -12.50M | -4.86M | -0.01M | -0.01M | -0.01M |
| Net income from continuing ops | -71.64M | -79.46M | -68.74M | -50.52M | -32.20M |
| Net income applicable to common shares | - | -79.46M | -68.74M | -50.52M | -32.20M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 99.90M | 226.15M | 231.14M | 152.35M | 115.55M |
| Other current assets | - | - | - | - | 0.65M |
| Total liab | 42.75M | 102.18M | 103.94M | 225.87M | 52.69M |
| Total stockholder equity | 57.15M | 123.98M | 127.20M | -73.52M | 62.86M |
| Other current liab | - | 12.51M | 26.66M | 19.68M | 3.74M |
| Common stock | 0.03M | 0.03M | 0.03M | 0.00M | 0.00M |
| Capital stock | 0.03M | 0.03M | 0.03M | 0.00M | - |
| Retained earnings | -274.97M | -195.51M | -126.77M | -76.25M | -44.05M |
| Other liab | - | 9.20M | 19.86M | 22.59M | - |
| Other assets | 2.31M | 2.63M | 2.31M | 2.32M | 0.00M |
| Cash | 63.71M | 143.51M | 170.36M | 39.26M | 59.57M |
| Total current liabilities | 21.84M | 33.22M | 45.19M | 38.28M | 21.33M |
| Current deferred revenue | - | - | - | - | 16.50M |
| Net debt | - | - | - | - | -59.57M |
| Other stockholder equity | - | - | - | 0.03M | 0.51M |
| Property plant equipment | 29.39M | 72.89M | 52.01M | 48.21M | - |
| Total current assets | 68.20M | 150.63M | 176.83M | 101.82M | 108.81M |
| Net tangible assets | 57.15M | 123.98M | 127.20M | -73.52M | - |
| Short term investments | - | - | 0.00M | 59.03M | 47.34M |
| Net receivables | 0.00M | 3.10M | 2.44M | 2.08M | 1.25M |
| Accounts payable | 2.51M | 3.97M | 3.71M | 2.80M | 1.09M |
| Accumulated other comprehensive income | - | - | - | - | -0.00M |
| Non currrent assets other | 2.31M | 2.31M | 2.31M | 2.32M | -0.00M |
| Non current assets total | 31.70M | 75.52M | 54.31M | 50.53M | 6.73M |
| Capital lease obligations | 27.47M | 69.69M | 47.09M | 42.33M | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | -0.04M | -0.49M | -0.61M | 59.00M | -10.68M |
| Change to liabilities | - | -22.41M | -22.80M | 4.85M | -3.19M |
| Total cashflows from investing activities | - | -0.49M | -0.61M | 57.82M | -12.85M |
| Total cash from financing activities | 0.33M | 4.23M | 55.91M | 116.42M | 26.04M |
| Change to operating activities | - | -4.79M | -9.03M | -12.11M | -2.64M |
| Net income | -71.64M | -79.46M | -68.74M | -50.52M | -32.20M |
| Change in cash | -74.05M | -79.80M | -26.84M | 131.09M | -20.30M |
| Begin period cash flow | 86.54M | 145.82M | 172.66M | 41.57M | 61.88M |
| End period cash flow | 12.50M | 66.01M | 145.82M | 172.66M | 41.57M |
| Total cash from operating activities | -74.33M | -83.55M | -82.14M | -43.15M | -33.49M |
| Issuance of capital stock | 0.30M | 4.07M | 56.40M | 117.74M | 25.95M |
| Depreciation | 11.45M | 11.68M | 11.03M | 10.94M | 4.36M |
| Change to account receivables | 0.00M | 3.00M | -1.11M | -0.02M | -1.01M |
| Sale purchase of stock | - | - | - | - | 0.00M |
| Other cashflows from financing activities | - | - | -1.90M | -1.76M | -1.76M |
| Change to netincome | - | 8.44M | 8.51M | 3.71M | 1.19M |
| Capital expenditures | 0.21M | 0.52M | 0.61M | 1.18M | 2.17M |
| Change in working capital | -24.61M | -24.20M | -32.94M | -7.28M | -6.83M |
| Stock based compensation | 4.60M | 8.40M | 8.51M | 3.60M | 2.11M |
| Other non cash items | - | - | - | 0.11M | - |
| Free cash flow | -74.55M | -84.07M | -82.75M | -44.33M | -35.66M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SQZB SQZ Biotechnologies Company |
- -% |
0.02 | - | - | 0.06 | 0.44 | 0.99 | -0.01 |
| NVO Novo Nordisk A/S |
-1.06 2.73% |
37.81 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-5.64 1.08% |
515.02 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
- -% |
920.69 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, infectious diseases, and other serious conditions in Massachusetts. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV and SQZ-eAPC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
200 Arsenal Yards Boulevard, Watertown, MA, United States, 02472
617 758 8672
53
| Name | Title | Year Born |
|---|---|---|
| Mr. Lawrence J. Knopf Esq. | General Counsel & Secretary | 1962 |
| Dr. Marshelle Smith Warren M.D. | Chief Medical Officer | 1963 |
| Dr. Robert S. Langer Jr., Ph.D., ScD | Co-Founder & Member of Scientific Advisory Board | 1949 |
| Ms. Ipsita Roymoulik Ph.D. | Senior Vice President of CMC & QUALITY | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.